Elaine O'Hara - Mar 1, 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
EVP, Chief Strategy Officer
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
3/3/2023, 04:02 PM
Next filing
Mar 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to buy) Award $0 +67.9K $0.00 67.9K Mar 1, 2023 Common Stock 67.9K $6.86 Direct F1
transaction NVAX Restricted Stock Units Award $0 +58.8K $0.00 58.8K Mar 1, 2023 Common Stock 58.8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") 2023 Inducement Plan (the "Plan") will vest on the first anniversary of the March 1, 2023 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock.
F3 The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date.